True Link Financial Advisors’s AstraZeneca AZN Stock Holding History

True Link Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-259	Closed	-$51.1K	–	124
2026 Q1	$51.1K	Buy	+259	New	+$49.9K	﹤0.01%	210

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

True Link Financial Advisors's AZN Position: Q2 2026 in Review

True Link Financial Advisors sold out of AstraZeneca (AZN) in Q2 2026, closing a stake of 259 shares — an estimated $51.1K sold.

True Link Financial Advisors first reported a position in AZN in Q1 2026 and held it in 1 quarter. The position peaked at $51.1K in Q1 2026. 1,507 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

True Link Financial Advisors reported no remaining AstraZeneca position as of Q2 2026 after selling out during the quarter.
True Link Financial Advisors sold 259 AstraZeneca shares in Q2 2026, an estimated $51.1K.
True Link Financial Advisors first reported a position in AstraZeneca in Q1 2026 and held it in 1 quarter.
True Link Financial Advisors's AstraZeneca position peaked at $51.1K in Q1 2026.
1,507 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on True Link Financial Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.